60044
Medtronic Intersect ENT Propel Mini 16mm, Straight
$849.00
box of 1
In Stock: 1 Each
Expiration:
In-Date
Express: Need it tomorrow? Order in next 2 hours 8 minutes and choose overnight shipping at checkout.
Medtronic Biosyn undyed 30" GS-21 taper
$94.50 box of 36
Medtronic Monosof black 30" SC-2 cutting
$2.55 packets
Medtronic Biosyn undyed 18" P-12 Reverse Cutting Needle
$8.00 packets
Medtronic Monosof black 60" GS-26 taper
$7.00 packets
Medtronic Biosyn undyed 36" GS-21 taper
$3.40 packets
Description
Medtronic Intersect ENT Propel Steroid-Releasing Implant
Intersect ENT has developed the PROPEL dissolvable implant for chronic sinusitis patients undergoing sinus surgery; the first and only sinus surgery product backed by Level 1-A evidence. PROPEL is the first of a new category of products offering localized, controlled drug delivery directly to the sinus tissue. Inserted by a physician to maintain the surgical opening, the spring-like implant expands to prop open the ethmoid sinus and gradually delivers an advanced corticosteroid (mometasone furoate) with anti-inflammatory properties directly to the sinus lining as the implant dissolves.
Additional information
| Size | 1 |
|---|---|
| Arms | N/A |
| Manufacturer | |
| Type | Propel |
| Unit | box of 1 |
- FDA Product Code: OWO
- FDA Product Code Name: Drug-eluting sinus stent
- GMDN Term Code: 61370
- GMDN Term Name: Drug-eluting paranasal sinus stent
- GMDN Term Description: A bioabsorbable device with a drug coating intended to be implanted into a paranasal sinus (e.g., frontal, sphenoidal, ethmoidal, maxillary) to maintain sinus patency in the treatment of chronic sinusitis. The drug coating is intended to reduce inflammation and polyps to facilitate the separation of sinus mucosal tissues. The device is made of synthetic polymer(s) capable of being degraded and absorbed by body tissues, and is designed to allow for the slow release of the drug coating. It is endoscopically implanted via the nasal passageway; disposable devices associated with implantation may be included.
Intersect ENT
Intersect ENT, now part of Medtronic, specializes in drug-delivery sinus implants designed to treat chronic rhinosinusitis and improve postoperative outcomes following sinus surgery. Its core products—PROPEL, PROPEL Mini, and PROPEL Contour—are bioresorbable steroid-eluting implants that deliver anti-inflammatory medication directly to the sinus tissue while propping open the sinus cavities during healing. Intersect ENT also developed the SINUVA implant, an in-office option for recurrent nasal polyps. By combining localized drug delivery with mechanical support, Intersect ENT offers ENT specialists innovative, minimally invasive solutions to reduce inflammation, minimize the need for oral steroids, and improve long-term sinus health.